Higher-dose palopegteriparatide treatment for adults with hypoparathyroidism.

A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

This 78-week test will see if giving adults with chronic hypoparathyroidism higher doses of palopegteriparatide (above 30 µg/day) is safe and better controls their calcium levels.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 36 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Ascendis Pharma A/S (Industry-sponsored)
• Drugs / interventions: methotrexate
• Locations: 3 sites (Reno, Nevada and 2 other locations)
• Trial ID: NCT07081997 on ClinicalTrials.gov

What this trial studies

This Phase 3 randomized trial enrolls adults who are already taking palopegteriparatide at or above 30 µg/day and continues subcutaneous palopegteriparatide for 78 weeks. Participants will be individually and progressively titrated to an optimal dose at pre-specified dose levels above 30 µg/day. The trial collects safety and efficacy data to provide additional evidence about using doses greater than 30 µg/day. All laboratory confirmations and dosing adjustments are performed according to the protocol before and during randomization.

Who should consider this trial

Good fit: Adults (≥18 years) with chronic hypoparathyroidism (postsurgical, autoimmune, genetic, or idiopathic) who are already receiving palopegteriparatide at doses of 30 µg/day or higher and meet the trial's laboratory requirements are ideal candidates.

Not a fit: People who are not already on palopegteriparatide at ≥30 µg/day or who cannot meet required lab ranges (for example, 25(OH) vitamin D outside 20–80 ng/mL) would not be eligible and are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, the treatment could allow some patients to use higher palopegteriparatide doses to better maintain normal calcium levels and reduce dependence on oral calcium or active vitamin D.

How similar studies have performed: Prior clinical work with palopegteriparatide (TransCon PTH) has shown promise in hypoparathyroidism, but dosing above 30 µg/day remains less well established and is the focus of this trial.

Eligibility criteria

Inclusion criteria:

1. Males and females, ≥18 years of age at the time of providing informed consent
2. Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
3. Receiving doses of palopegteriparatide at or above 30 µg/day

   For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:

   Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening

   For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium
4. Confirmation of laboratory parameters (Central and Local) within 2 weeks of screening visit and prior to randomization:

25(OH) vitamin D levels of 20 - 80 ng/mL (49 - 200 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range

* Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
* Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L)

  5\. BMI 17- 40 kg/m2 at Screening

  6\. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand

  7\. eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

Exclusion criteria

1. Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin \>30 µg/day, or systemic corticosteroids (other than as replacement therapy)
4. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
5. Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
6. Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
7. Use of osteoporosis therapies other than bisphosponate known to influence calcium and bone metabolism within 2 years prior to Screening. Note: use of bisphosphonate (oral or intravenous \[IV\] is not exclusionary
8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.
9. Increased risk for osteosarcoma
10. Women who are pregnant, intend to become pregnant, or are lactating
11. Male who has a female partner who intends to become pregnant or is of childbearing potential and is unwilling to use adequate contraceptive methods during the trial
12. Diagnosed drug or alcohol dependence within 3 years prior to Screening
13. Chronic or severe cardiac disease within 26 weeks prior to Screening
14. Cerebrovascular accident within 5 years prior to Screening.
15. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
16. Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.
17. Known allergy or sensitivity to PTH or any of the excipients \[metacresol, mannitol, succinic acid, NaOH/(HCl)\] of the investigational product

Where this trial is running

Reno, Nevada and 2 other locations

• Ascendis Pharma Investigational Site — Reno, Nevada, United States (Recruiting)
• Ascendis Pharma Investigational Site — New York, New York, United States (Recruiting)
• Ascendis Pharma Investigational Site — Spokane Valley, Washington, United States (Recruiting)

Study contacts

• Study coordinator: Ascendis Registry Inquiries

Conditions Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases; Parathyroid Hormone; TransCon PTH; PTH; Prodrug; Sustained Release